Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015, Article ID 931058, 11 pages
http://dx.doi.org/10.1155/2015/931058
Research Article

Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson’s Disease

1Department of Geriatrics Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China
2Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
3Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China
4Department of Emergency Neurology, The Affiliated Hospital of Medical College Qingdao University, Qingdao 266021, China
5Department of Neurology, Shanghai 9th People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
6Department of Neurology, Suzhou Municipal Hospital Affiliated to Nanjing Medicine University, Suzhou 215001, China

Received 22 July 2015; Revised 13 October 2015; Accepted 20 October 2015

Academic Editor: Francisco Grandas

Copyright © 2015 Xiang-Yun Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Kawakami and T. Ichikawa, “The role of α-synuclein and LRRK2 in tau phosphorylation,” Parkinson's Disease, vol. 2015, Article ID 734746, 10 pages, 2015. View at Publisher · View at Google Scholar
  2. R. Perfeito, T. Cunha-Oliveira, and A. C. Rego, “Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease—resemblance to the effect of amphetamine drugs of abuse,” Free Radical Biology and Medicine, vol. 53, no. 9, pp. 1791–1806, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Zaltieri, F. Longhena, M. Pizzi, C. Missale, P. Spano, and A. Bellucci, “Mitochondrial dysfunction and α-synuclein synaptic pathology in parkinson’s disease: who’s on first?” Parkinson's Disease, vol. 2015, Article ID 108029, 10 pages, 2015. View at Publisher · View at Google Scholar
  4. B. J. Stansley and B. K. Yamamoto, “L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells,” Neuropharmacology, vol. 67, pp. 243–251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Smeyne and R. J. Smeynen, “Glutathione metabolism and Parkinson's disease,” Free Radical Biology and Medicine, vol. 62, pp. 13–25, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Jenner, “Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease,” Acta Neurologica Scandinavica, Supplement, vol. 146, pp. 6–13, 1993. View at Google Scholar · View at Scopus
  7. S. Vali, R. B. Mythri, B. Jagatha et al., “Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model,” Neuroscience, vol. 149, no. 4, pp. 917–930, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. D. S. Albers and M. F. Beal, “Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease,” Journal of Neural Transmission. Supplement, no. 59, pp. 133–154, 2000. View at Google Scholar · View at Scopus
  9. I. Cacciatore, L. Baldassarre, E. Fornasari, A. Mollica, and F. Pinnen, “Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 240146, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. D. S. Miller, B. Bauer, and A. M. S. Hartz, “Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy,” Pharmacological Reviews, vol. 60, no. 2, pp. 196–209, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. D. S. Miller, “Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier,” Trends in Pharmacological Sciences, vol. 31, no. 6, pp. 246–254, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Chen, S. Agarwal, N. M. Shaik, C. Chen, Z. Yang, and W. F. Elmquist, “P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib,” Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 3, pp. 956–963, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Wei, H. Sun, F. Wang, and G. Liu, “H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein,” Cancer Chemotherapy and Pharmacology, vol. 67, no. 5, pp. 1017–1025, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. L.-M. Chen, Y.-J. Liang, X. Zhang et al., “Reversal of P-gp-mediated multidrug resistance by bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue,” Anticancer Research, vol. 29, no. 11, pp. 4597–4604, 2009. View at Google Scholar · View at Scopus
  15. J. Thomas, J. Wang, H. Takubo, J. Sheng, S. de Jesus, and K. S. Bankiewicz, “A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization,” Experimental Neurology, vol. 126, no. 2, pp. 159–167, 1994. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Wang, F. Zhao, Y. Jin et al., “Effects of exogenous glutathione on arsenic burden and NO metabolism in brain of mice exposed to arsenite through drinking water,” Archives of Toxicology, vol. 85, no. 3, pp. 177–184, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. K. S. Shin, H. S. Choi, T. T. Zhao et al., “Neurotoxic effects of berberine on long-term l-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease,” Archives of Pharmacal Research, vol. 36, no. 6, pp. 759–767, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. W.-L. Kuan, E. Poole, M. Fletcher et al., “A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial Complex I activity,” Journal of Experimental Medicine, vol. 209, no. 1, pp. 1–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Yang, Z. He, Q. Zhang et al., “Pre-ischemic treadmill training for prevention of ischemic brain injury via regulation of glutamate and its transporter GLT-1,” International Journal of Molecular Sciences, vol. 13, no. 8, pp. 9447–9459, 2012. View at Google Scholar
  20. J. Sian, D. T. Dexter, A. J. Lees, S. Daniel, P. Jenner, and C. D. Marsden, “Glutathione-related enzymes in brain in Parkinson's disease,” Annals of Neurology, vol. 36, no. 3, pp. 356–361, 1994. View at Publisher · View at Google Scholar · View at Scopus
  21. D. W. Lee, D. Kaur, S. J. Chinta, S. Rajagopalan, and J. K. Andersen, “A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease,” Antioxidants and Redox Signaling, vol. 11, no. 9, pp. 2083–2094, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. S. J. Chinta, M. J. Kumar, M. Hsu et al., “Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration,” Journal of Neuroscience, vol. 27, no. 51, pp. 13997–14006, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. U. Wüllner, P.-A. Löschmann, J. B. Schulz et al., “Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones,” NeuroReport, vol. 7, no. 4, pp. 921–923, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Gilgun-Sherki, E. Melamed, and D. Offen, “Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier,” Neuropharmacology, vol. 40, no. 8, pp. 959–975, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. Y.-Q. Shan, Y.-P. Zhu, J. Pang et al., “Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function,” Biological and Pharmaceutical Bulletin, vol. 36, no. 10, pp. 1562–1569, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. Q.-M. Xie, H.-F. Tang, J.-Q. Chen, and R.-L. Bian, “Pharmacological actions of tetrandrine in inflammatory pulmonary diseases,” Acta Pharmacologica Sinica, vol. 23, no. 12, pp. 1107–1113, 2002. View at Google Scholar · View at Scopus
  27. Y. Chen, Y.-H. Tsai, and S.-H. Tseng, “The potential of tetrandrine as a protective agent for ischemic stroke,” Molecules, vol. 16, no. 9, pp. 8020–8032, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Asanuma, I. Miyazaki, and N. Ogawa, “Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease,” Neurotoxicity Research, vol. 5, no. 3, pp. 165–176, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Miyazaki and M. Asanuma, “Dopaminergic neuron-specific oxidative stress caused by dopamine itself,” Acta Medica Okayama, vol. 62, no. 3, pp. 141–150, 2008. View at Google Scholar · View at Scopus
  30. R. Pedrosa and P. Soares-da-Silva, “Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine,” British Journal of Pharmacology, vol. 137, no. 8, pp. 1305–1313, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. J. P. E. Spencer, A. Jenner, J. Butler et al., “Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease,” Free Radical Research, vol. 24, no. 2, pp. 95–105, 1996. View at Publisher · View at Google Scholar · View at Scopus
  32. R. M. Kostrzewa, J. P. Kostrzewa, and R. Brus, “Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum,” Amino Acids, vol. 19, no. 1, pp. 183–199, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Miyazaki and M. Asanuma, “Approaches to prevent dopamine quinone-induced neurotoxicity,” Neurochemical Research, vol. 34, no. 4, pp. 698–706, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. P. F. Worth, “How to treat Parkinson's disease in 2013,” Clinical Medicine, vol. 13, no. 1, pp. 93–96, 2013. View at Publisher · View at Google Scholar · View at Scopus